We are pleased to share that ExploRNA Tx has recently secured patent protection in the United States, Japan, and at the European Patent Office (EPO) for an invention covering novel solutions targeting the 5’ end of mRNA, including novel 5’-end cap analogs—a key component of mRNA technology.
The patent family protects multiple innovations in the area of mRNA 5’ end (cap), including our flagship product, AvantCap.
This is a strong validation of our innovative science and our commitment to building durable technological advantage—another step forward in the development and commercialization of RNA-based solutions.
The granted patent number WO2021162567 is entitled:
“Novel mRNA 5′-end cap analogs, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide”.
You can learn more about the AvantCap modification reading our teams peer-reviewed publication here: https://pubs.acs.org/doi/full/10.1021/jacs.3c12629
Picture 1. N6-benzyl modification in the close-up on the partial structure of one of the AvantCap cap analogs.
AvantCap Q1 and other ExploRNA’s proprietary cap analogs are available at explorna.com/shop.
